November 13th 2025
Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.
November 6th 2025
Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.
October 30th 2025
Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.
October 23rd 2025
Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.
October 3rd 2025
Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.
September 30th 2025
Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.
September 17th 2024
Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.
September 16th 2024
Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.
September 10th 2024
Yuan Yuan, MD, PhD, discusses the potential shift towards minimizing surgical intervention for lymph node management in breast cancer.
July 7th 2023
Yuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.
June 1st 2023
Yuan Yuan, MD, PhD, discusses the importance of clinical trial participation and enrollment in patients with breast cancer.